Medindia

X

PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer

Thursday, July 17, 2008 General News J E 4
Advertisement
BOSTON, July 16 PAREXEL InternationalCorporation (Nasdaq: PRXL), a leading global biopharmaceutical servicesorganization, announced today that it has promoted Mark A. Goldberg, M.D., toChief Operating Officer (COO). Dr. Goldberg previously served as President ofClinical Research Services and Perceptive Informatics at PAREXEL. He willcontinue to oversee these areas of the Company and report to Josef vonRickenbach, Chairman and Chief Executive Officer of PAREXEL.

"Dr. Goldberg has been an asset to PAREXEL's executive management team formore than 11 years. His appointment as COO is in recognition of his strongleadership skills and increasing responsibilities, especially as we haveexpanded our clinical development capabilities and global footprint, includingthe recent extension of our capabilities in the Asia-Pacific region," said Mr.von Rickenbach. "Dr. Goldberg has led the strong performance in ClinicalResearch Services, our largest business segment, and has helped to buildPerceptive Informatics into a leading provider of advanced technologies thatfacilitate the clinical development process. We look forward to his continuedcontributions in meeting our operational and financial goals, and solidifyingour position as a global leader in full service clinical development."

Dr. Goldberg stated, "In this role, I look forward to working with ourglobal management team to capitalize on the strong market opportunity forglobal biopharmaceutical services. My focus will include further strengtheningour client relationships, as well as leveraging PAREXEL's leadership role inthe convergence of services and technology in support of clinical research."

Dr. Goldberg's combined medical, technical, and clinical researchexpertise has positioned him well to lead Clinical Research Services andPerceptive Informatics at PAREXEL. He joined PAREXEL in 1997, establishing theCompany's Medical Imaging Group to leverage imaging data as a surrogate endpoint, or biomarker, in evaluating the safety and efficacy of new products. In2000, Dr. Goldberg was involved in establishing Perceptive Informatics todeliver advanced technology solutions that improve development andcommercialization processes for the biopharmaceutical industry. Today,Perceptive Informatics has a portfolio of products and services includingmedical imaging, Interactive Voice and Web Response Systems, and theindustry-leading IMPACT(R) Clinical Trial Management System (CTMS), which hasapproximately 26,000 users-the largest global CTMS user-base. In 2005, Dr.Goldberg took responsibility for the Clinical Research Services business andhas achieved strong performance in new business wins, revenue growth, andprofitability improvement. During this time, he continued to expand theofferings of the business, which provides capabilities across a broad range oftherapeutic areas and all phases of clinical research.

Prior to joining PAREXEL, Dr. Goldberg served as President and Director ofWorldCare, Inc., a tele-health spin-off from Massachusetts General Hospital(MGH), which he helped found. Dr. Goldberg holds a degree in Computer Scienceand Engineering from the Massachusetts Institute of Technology (M.I.T.), andan M.D. degree from the University of Massachusetts Medical School. Hecompleted residency training in Diagnostic Radiology at MGH where he alsoserved as Chief Resident. Dr. Goldberg was a staff radiologist at MGH andmaintains an appointment as Consultant in Radiology.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceuticalservices organization, providing a broad range of knowledge-based contractresearch, medical communications and consulting services to the worldwidepharmaceutical, biotechnology and medical device industries. Committed toproviding solutions that expedite time-to-market and peak-market penetration,PAREXEL has developed significant expert
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VSP Vision Care Takes Tax-Exempt Appeal to Supreme...
S
Immunosyn Announces Proposed Agreements for Distri...